 |
Title
|
|
|
|
Phase 
|
|
|
|
Protocol
IDs
|
|
|
| |
Pharmacokinetic Study on the Addition of Aprepitant to Cisplatin - Etoposide Treatment in Lung Cancer Patients
|
|
|
|
Phase IV
|
|
|
|
UMCN-AKF 07.02
EudraCTnr 2007-003347-73, NCT00588835
|
|
| |
Enbrel Versus Placebo With Radiation Therapy to Combat Fatigue and Cachexia
|
|
|
|
Phase III, Phase II
|
|
|
|
001-0015-211
NCT00127387
|
|
| |
A Study for Small Cell Lung Cancer (SCLC) in Extensive Disease Stage
|
|
|
|
Phase III, Phase II
|
|
|
|
Haema CBF SCLC UK/AS 01
NCT00168896
|
|
| |
A Study Comparing Etoposide/Cisplatin With Irinotecan/Cisplatin to Treat Extensive Disease Small Lung Cancer
|
|
|
|
Phase III
|
|
|
|
CRCST-L-0001
NCT00349492
|
|
| |
Partnership for Healthy Seniors
|
|
|
|
Phase III
|
|
|
|
IRB00000063
NCT00379743
|
|
| |
Etoposide and Cisplatin or Carboplatin as First-Line Chemotherapy With or Without Pravastatin in Treating Patients With Small Cell Lung Cancer
|
|
|
|
Phase III
|
|
|
|
CRUK-LUNGSTAR
EU-20649, ISRCTN56306957, EUDRACT-2005-005821-71, UCL-BRD/05/129, NCT00433498
|
|
| |
Cisplatin, Etoposide, and Two Different Schedules of Radiation Therapy in Treating Patients With Limited Stage Small Cell Lung Cancer
|
|
|
|
Phase III
|
|
|
|
CHNT-CONVERT
CHNT-CTAAC-CONVERT-C17052/A8152, EU-20669, NCT00433563
|
|
| |
Study of Picoplatin Efficacy After Relapse
|
|
|
|
Phase III
|
|
|
|
0601
NCT00465491
|
|
| |
STAD-1 Small Cell Lung Cancer Toxicity Adjusted Dosing Study
|
|
|
|
Phase III
|
|
|
|
STAD-1
EudraCT number 2006-003995-36, NCT00526396
|
|
| |
AMR PH GL 2007 CL 001 Phase 3 Trial in Patients With Small Cell Lung Cancer After Failure of First-Line Chemotherapy
|
|
|
|
Phase III
|
|
|
|
AMR PH GL 2007 CL 001
NCT00547651
|
|
